Uncategorized
Kelman lecturer works toward new treatment for corneal endothelial dysfunction
SAN DIEGO — Shigeru Kinoshita, MD, PhD, detailed the clinical application of cultivated cells and the medical treatment for corneal endothelial dysfunction during the Charles D. Kelman Innovator’s Lecture here.“We now have PKP, DSEK or DMEK, but in addition to that, we may be able to add additional treatments such as the cell injection of the cultivated corneal endothelial cells or the Rho-kinase inhibitor and eye drops,” he said at the American Society of Cataract and Refractive Surgery annual meeting.